by John Conrad | Feb 18, 2026 | Policy News
John Conrad, President and CEO of the Illinois Biotechnology Innovation Organization (iBIO), released the following statement in response to Governor JB Pritzker’s Budget Address: “iBIO commends Governor Pritzker for the proactive economic development initiatives...
by John Conrad | Aug 1, 2025 | Member News, NewsBrief
Chicago biotech startup ClostraBio has secured GRAS (Generally Recognized as Safe) status for its flagship probiotic ingredient CLB101™, clearing the path for the first commercially available strain of Anaerostipes caccae in the U.S. What Makes It Different Unlike...
by John Conrad | Sep 19, 2024 | NewsBrief
Syntax Bio has launched with $15 million in funding from notable investors, including Astellas Venture Management LLC and Illumina Ventures. The Chicago-based startup is pioneering a novel approach to cell therapy with its Cellgorithm platform. Syntax Bio’s...
by John Conrad | Jun 21, 2024 | iBIO News
Illinois Biotechnology Innovation Organization Announces Rheoxtech as Winner of Inaugural Timothy P. Walbert Entrepreneurship Impact Award CHICAGO, IL (June 21, 2024) – The Illinois Biotechnology Innovation Organization (iBIO) is pleased to announce that Rheoxtech has...
by John Conrad | Jun 6, 2024 | NewsBrief
The biopharma sector has undergone significant changes in venture funding and investment trends during the first quarter of 2024, according to a recent PitchBook report. Despite a decrease in deal count, the sector saw an increase in venture funding, with $7.4 billion...
